Aug 16, 2021 7:05am EDT Virios Therapeutics CEO Highlights Novel Therapeutic Approach for Treating Fibromyalgia and Irritable Bowel Syndrome in Stock News Now Video Interview
Aug 12, 2021 7:05am EDT Virios Therapeutics Announces Second Quarter 2021 Financial Results and Provides Corporate Update
Aug 05, 2021 7:05am EDT Virios Therapeutics to Report Second Quarter 2021 Financial Results and Provide Corporate Update on Thursday, August 12, 2021
Jul 26, 2021 7:05am EDT Virios Therapeutics Highlights Clinical Sites Fully Operational in Phase 2b Fibromyalgia Study Featuring FDA “Fast Track” Review Designated Antiviral Therapy, Oral IMC-1
Jun 09, 2021 7:05am EDT Virios Therapeutics Highlights Safety Data from Phase 2a Fibromyalgia Trial at the International Association for the Study of Pain (IASP) World Congress
Jun 04, 2021 7:05am EDT Virios Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating IMC-1 in Patients with Fibromyalgia
Jun 02, 2021 7:05am EDT Virios Therapeutics Presents Phase 2a Fibromyalgia Trial Data on Efficacy Analyses of Key Secondary Endpoints at the EULAR European Congress of Rheumatology
May 24, 2021 7:05am EDT Virios Therapeutics Announces Oral Presentation of Clinical Data at Digestive Disease Week® (DDW)
